Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.45 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18557032 | 1.00 | SMN1; SMN2 (0.68) | SMN1; SMN2POLBALDH1A1TP53CES2 | |
| SCHEMBL30542346 | 1.00 | SMN1; SMN2 (0.68) | SMN1; SMN2POLBALDH1A1TP53CES2 | |
| SCHEMBL7119913 | 1.00 | SMN1; SMN2 (0.68) | SMN1; SMN2POLBALDH1A1TP53CES2 | |
| SCHEMBL30542347 | 1.00 | SMN1; SMN2 (0.68) | SMN1; SMN2POLBALDH1A1TP53CES2 | |
| SCHEMBL15443235 | 1.00 | SMN1; SMN2 (0.68) | SMN1; SMN2POLBALDH1A1TP53CES2 | |
| SCHEMBL18760457 | 1.00 | SMN1; SMN2 (0.68) | SMN1; SMN2POLBALDH1A1TP53CES2 | |
| SCHEMBL12326212 | 1.00 | SMN1; SMN2 (0.68) | SMN1; SMN2POLBALDH1A1TP53CES2 | |
| SCHEMBL18552 | 1.00 | SMN1; SMN2 (0.68) | SMN1; SMN2POLBALDH1A1TP53CES2 | |
| SCHEMBL29058069 | 1.00 | SMN1; SMN2 (0.68) | SMN1; SMN2POLBALDH1A1TP53CES2 | |
| SCHEMBL6966832 | 1.00 | SMN1; SMN2 (0.68) | SMN1; SMN2POLBALDH1A1TP53CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140030609-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND ENERGY STORAGE DEVICE USING SAME | UBE INDUSTRIES, LTD. (JP) | 2014-01-30 | — | — | US | claimed |
| WO-2026090509-A1 | SPIRO HETEROCYCLIC CDK2 INHIBITORS | ARCHITECT THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| CN-109535155-B | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | 艾伯维公司 | 2022-07-12 | — | — | CN | disclosed |
| US-20210346369-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2021-11-11 | — | — | US | disclosed |
| US-20200345717-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2020-11-05 | — | — | US | disclosed |
| CN-109562113-A | Spirocyclo-rongeur for target protein degradation | C4医药公司 | 2019-04-02 | — | — | CN | disclosed |
| WO-2018210828-A1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2018-11-22 | — | — | WO | disclosed |
| EP-2768830-B1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2018-08-29 | — | — | EP | disclosed |
| US-20180221363-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2018-08-09 | — | — | US | disclosed |
| US-9877958-B2 | Apoptosis-induced agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2018-01-30 | — | — | US | disclosed |
| WO-1996004273-A1 | NEW PYRAZOLE DERIVATIVES AS ANGIOTENSIN II ANTAGONIST | J. URIACH & CIA, S.A. (ES) | 1996-02-15 | — | — | WO | disclosed |
| WO-1995033761-A1 | STEROID DERIVATIVES FOR TREATMENT OF 5 ALPHA REDUCTASE | SMITHKLINE BEECHAM CORPORATION (US) | 1995-12-14 | — | — | WO | disclosed |
| CN-1098725-A | Based on porous stretched article of acrylic resin and preparation method thereof | NEW JAPAN CHEM CO LTD (JP) | 1995-02-15 | — | — | CN | disclosed |
| EP-0236074-B1 | 2BETA-SUBSTITUTED THIOMETHYLPENICILLIN DERIVATIVES AND THEIR PREPARATION AND USE | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1992-01-08 | — | — | EP | disclosed |
| US-4861768-A | 2 β-substituted thiomethylpenicillin derivatives and their preparation and use | TAIHO PHARMACEUTICAL COMPANY, LIMITED (JP) | 1989-08-29 | — | — | US | disclosed |
| EP-0236074-A1 | 2Beta-substituted thiomethylpenicillin derivatives and their preparation and use | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1987-09-09 | — | — | EP | disclosed |
| US-4668514-A | Penicillin derivatives | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1987-05-26 | — | — | US | disclosed |
| US-4562073-A | BETA-LACTAMASE INHIBITORS | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1985-12-31 | — | — | US | disclosed |
| US-4529592-A | Substituted in position 2 with a (4,5-diester-1,2,3-triazol-3-yl)alkyl group | TAIHO PHARMACEUTICAL COMPANY, LIMITED (JP) | 1985-07-16 | — | — | US | disclosed |
| EP-0138523-A1 | Penicillin derivatives and process for preparing the same (11111) | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1985-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200345717-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BAX, BCL2, BCL3 | SMN1; SMN2 3576/4885POLB 1957/4885ALDH1A1 4319/4885 |
| US-20210346369-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BAX, BCL2, BCL3 | SMN1; SMN2 3576/4885POLB 1957/4885ALDH1A1 4319/4885 |
| US-20180221363-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BAX, BCL2, BCL3 | SMN1; SMN2 3576/4885POLB 1957/4885ALDH1A1 4319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.